| Literature DB >> 26250727 |
Angela Dispenzieri1, Francis Buadi2, Shaji K Kumar2, Craig B Reeder3, Tamur Sher4, Martha Q Lacy2, Robert A Kyle2, Joseph R Mikhael3, Vivek Roy4, Nelson Leung2, Martha Grogan5, Prashant Kapoor2, John A Lust2, David Dingli2, Ronald S Go2, Yi Lisa Hwa2, Suzanne R Hayman2, Rafael Fonseca3, Sikander Ailawadhi4, P Leif Bergsagel3, Ascher Chanan-Khan4, S Vincent Rajkumar2, Stephen J Russell2, Keith Stewart3, Steven R Zeldenrust2, Morie A Gertz2.
Abstract
Immunoglobulin light chain amyloidosis (AL amyloidosis) has an incidence of approximately 1 case per 100,000 person-years in Western countries. The rarity of the condition not only poses a challenge for making a prompt diagnosis but also makes evidenced decision making about treatment even more challenging. Physicians caring for patients with AL amyloidosis have been borrowing and customizing the therapies used for patients with multiple myeloma with varying degrees of success. One of the biggest failings in the science of the treatment of AL amyloidosis is the paucity of prospective trials, especially phase 3 trials. Herein, we present an extensive review of the literature with an aim of making recommendations in the context of the best evidence and expert opinion.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26250727 DOI： 10.1016/j.mayocp.2015.06.009
Source DB: PubMed Journal: Mayo Clin Proc ISSN： 0025-6196 Impact factor: 7.616